Skip to content Skip to footer
Subscribe Now
NEWS

Novartis to Acquire Pikavation Therapeutics from Synnovation for ~$3B

Shots: Novartis has entered into a definitive agreement with Synnovation to acquire Pikavation Therapeutics (Synnovation’s subsidiary) & its portfolio of PI3Kα inhibitor programs, incl. SNV4818, a P-I/II asset for HR+/HER2- metastatic breast cancer & other solid tumors As per the deal, Synnovation will receive $2B upfront, & ~$1B in development, regulatory, & commercial milestones, representing…
2 days ago

Read more

NEWS

Voro Therapeutics Collaborates with Daiichi Sankyo to Develop Tumor-Activated ADCs

Shots: Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo via its Daiichi Sankyo Research Institute, San Diego to develop tumor-activated biologics using the PrimeBody platform The collaboration will focus on generating masked ADCs designed for tumor-selective activation, using proprietary masking domains & protease-cleavable linkers to improve therapeutic index  Voro will design &…
4 days ago

Read more

NEWS

Samsung Bioepis and Epis NexLab Collaborate with G2GBIO on Long-Acting Semaglutide Development

Shots: Samsung Bioepis & Epis NexLab have entered a research collaboration & license agreement with G2GBIO to develop novel therapeutics using proprietary microsphere-based sustained-release technology As per the deal, Samsung Bioepis will receive full licensing rights to a long-acting Semaglutide asset, an option to license another asset, & first negotiation rights for three additional assets,…
March 16, 2026

Read more

NEWS

Enodia Acquires Kezar’s Sec61 Program to Advance Targeted Protein Degradation Pipeline

Shots: Enodia has acquired Kezar’s Sec61-based discovery & development program assets, strengthening its understanding of Sec61 selectivity mechanisms & expanding translational insights to accelerate progress toward key clinical milestones As per the deal, Kezar will receive a $1M upfront, ~$127M in development, regulatory, & commercial milestones, plus tiered royalties on future net sales Enodia’s platform…
March 13, 2026

Read more

NEWS

PRISM BioLab and Receptor.AI Partner to Develop a Drug Discovery Platform

Shots: PRISM has partnered with Receptor.AI to develop an AI-navigated, physics-guided platform for discovering orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins & complex receptor systems Collaboration will combine PRISM’s PepMetics Tech, 3D small molecules designed to mimic α-helix & β-turn motifs, with Receptor.AI’s AI-driven molecular design engine to identify hit, lead, &…
March 13, 2026

Read more

NEWS

George Medicines Partners with Ahngook Pharmaceutical to Commercialize GMRx2 in Korea

Shots: George Medicines has entered into an exclusive licensing & supply agreement with Ahngook Pharmaceutical, granting rights to seek regulatory approval & commercialize GMRx2 in Korea for the treatment of Hypertension As per the deal, George Medicines will receive an upfront licensing fee, potential regulatory & commercial milestone payments, as well as stepped royalties on…
March 12, 2026

Read more

NEWS

Rapport Therapeutics Partners with Tenacia Biotechnology to Advance RAP-219 in Greater China

Shots: Rapport Therapeutics has granted Tenacia exclusive rights to develop & commercialize RAP-219 in Greater China across indications, incl. focal onset seizures (FOS) & bipolar mania, with Rapport retaining rights in other territories As per the deal, Rapport will receive $20M upfront & ~$308M in development & commercialization milestones & other payments, plus mid-single digits…
March 10, 2026

Read more

Load more